17
January
0
Comments
Revance Prices $100M Preapproved Offering Amid Shutdown
in Legal News
Law360 (January 17, 2019, 7:16 PM EST) — Biotechnology company Revance Therapeutics said on Thursday that it has priced a $100 million follow-on offering by way of a preapproved U.S. Securities and Exchange Commission filing that will allow the…
